Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms.
Clinical cancer research : an official journal of the American Association for Cancer Research Feb, 2013 | Pubmed ID: 23149820